Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (POST 4)
Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (Post 4)
Sponsor: Dr. Bob Sheldon
Listed as NCT01456481, this PHASE4 trial focuses on Vasovagal Syncope and remains ongoing. Sponsored by Dr. Bob Sheldon, it has been updated 12 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
-
Dec 2022 — Jun 2024 [monthly]
Active Not Recruiting PHASE4
-
May 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE4
▶ Show 7 earlier versions
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE4
-
Oct 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
-
Jun 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE4
Status: Unknown Status → Active Not Recruiting
-
Sep 2018 — Jun 2019 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dr. Bob Sheldon
- Vanderbilt University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Calgary, Canada , Edmonton, Canada , Halifax, Canada , Hamilton, Canada , Lodz, Poland , Minneapolis, United States , Montreal, Canada , Nashville, United States , Ottawa, Canada , Red Deer, Canada and 6 more locations